Tirzepatide side effects: The long-term picture, kidneys, and headaches

Tirzepatide is a prescription medication, and like every prescription medication it comes with side effects worth understanding before you start. This article walks through what the clinical trials recorded, what longer-term data does and does not yet show, and two questions people ask often: what tirzepatide does to the kidneys, and why some people get headaches on it.

This is general education, not medical advice. Your own risk picture depends on your health history, your other medications, and the judgment of the licensed provider who reviews your case.

The side effects that show up most often

In the phase 3 trial programs for the FDA-approved products, the most frequently reported side effects were gastrointestinal. Across the SURPASS trials in people with type 2 diabetes (N = 6,263), nausea was reported by 12 to 24% of participants taking tirzepatide, diarrhea by 12 to 22%, and vomiting by 2 to 13% [1].

In SURMOUNT-1, which studied adults with obesity or overweight, the rates by dose (5 mg, 10 mg, and 15 mg) were nausea 24.6%, 33.3%, and 31.0%; diarrhea 18.7%, 21.2%, and 23.0%; constipation 16.8%, 17.1%, and 11.7%; and vomiting 8.3%, 10.7%, and 12.2% [2].

Two patterns run through this data. Most of these events were mild to moderate, and most of them clustered during dose escalation rather than continuing indefinitely [1, 3]. That is why titration exists: doses step up slowly so the gut has time to adjust.

Less common but still regularly reported are dyspepsia (indigestion), abdominal pain, burping, decreased appetite, and injection site reactions.

Long-term side effects: What is known and what is not

The honest answer is that the long-term record is still being written. Tirzepatide received its first FDA approval in 2022, so the longest controlled data sets run a few years rather than a few decades.

What the multi-year data does suggest:

• Gastrointestinal effects tend to fade. The trial analyses consistently show GI events concentrated in the escalation phase, declining once a person settles onto a maintenance dose [1, 3].
• Kidney function generally held steady or improved in the trial populations, including reduced albuminuria [4]. More on this below.
• Weight regain after stopping is well documented across the GLP-1 class. This is a medication that treats an ongoing condition, not a course of antibiotics.

What is still open:

• Effects over 10 or 20 years of continuous use are unknown, because nobody has been on it that long.
• Long-term effects on muscle mass and bone density are an active research question, not a settled one.
• The thyroid C-cell tumor signal seen in rodents has not been resolved in humans one way or the other, which is why the labeled warning remains.

Anyone who tells you the long-term profile is fully characterized is ahead of the evidence.

Tirzepatide and kidneys

This is the area where the data looks contradictory at first glance, and the resolution matters.

In trials, tirzepatide looked kidney-protective. Studies in people with type 2 diabetes and obesity reported slowed decline in kidney function and reduced protein in the urine [4]. A systematic review reinforced that finding relative to comparison therapies [4].

In practice, rare cases of acute kidney injury have occurred. The mechanism is indirect. The FDA-approved labeling states that the gastrointestinal reactions associated with tirzepatide can lead to dehydration, which if severe could cause acute kidney injury, and notes postmarketing reports of acute kidney injury and worsening chronic renal failure with GLP-1 receptor agonists, sometimes requiring hemodialysis [5]. Most of those reported cases occurred in people who had been experiencing nausea, vomiting, diarrhea, or dehydration [5].

So the kidney risk is mostly a fluid risk. Severe vomiting or diarrhea that goes unmanaged is the pathway. Published case reports describe acute kidney injury after tirzepatide exposure in patients with existing diabetic kidney disease, including one requiring temporary dialysis [6].

Who should be especially careful, and should raise this with a provider before starting:

• Anyone with chronic kidney disease or reduced kidney function
• Anyone taking diuretics, ACE inhibitors, or ARBs, which change how the kidneys handle low fluid volume
• Anyone with a condition that already makes dehydration likely

The labeling advises monitoring kidney function when starting or escalating the dose in patients with renal impairment who report severe gastrointestinal reactions [5]. That monitoring happens through your own provider and your own lab work.

Headaches on tirzepatide

Headache appears in the trial data at modest rates. In one SURMOUNT trial in adults with type 2 diabetes and obesity or overweight, headache was reported by 5.13% of participants on 10 mg and 4.82% on 15 mg, compared with 2.86% on placebo. Dizziness followed a similar pattern, at 5.45% on 10 mg versus 1.59% on placebo [7].

Headaches on this medication usually trace back to something other than the drug acting directly on the head:

Dehydration. Eating less and drinking less go together, and nausea reduces fluid intake further. This is the most common explanation and the most fixable one.

Low blood sugar. Tirzepatide on its own rarely causes hypoglycemia, but combined with insulin or a sulfonylurea the risk rises considerably. Headache, shakiness, sweating, and confusion together are a blood sugar question, not a headache question.

Eating much less than usual. Appetite suppression is the intended effect. Skipping meals entirely is not, and it produces headaches in plenty of people who have never taken a GLP-1.

Call a provider if a headache is severe, sudden, unlike any headache you usually get, or comes with vision changes, confusion, or weakness.

Serious and rare reactions

These appear in the labeled warnings for the FDA-approved products and are worth knowing as general information, not as a reason to panic. They are uncommon.

• Pancreatitis. Severe, persistent abdominal pain, sometimes radiating to the back, sometimes with vomiting. Stop and seek care.
• Gallbladder problems, including gallstones. Rapid weight loss raises gallstone risk generally.
• Severe gastrointestinal disease. Tirzepatide has not been studied in people with severe gastroparesis and is not recommended there [5].
• Serious hypersensitivity reactions, including anaphylaxis and angioedema [5].
• Thyroid C-cell tumors, a boxed warning based on rodent studies, with a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Diabetic retinopathy. Rapid improvement in glucose control has been linked to temporary worsening [5].

Reducing the risk of side effects

None of this is a guarantee, and none of it replaces provider guidance. It is what the tolerability data points toward.

Stay ahead on fluids. This is the single highest-value habit, because it sits upstream of both the kidney risk and most headaches. Drink through the day, not just when thirsty.

Do not rush the titration. The trials escalated slowly for a reason, and the GI events cluster exactly where the dose moves [1, 3]. If a step up is rough, that is information for your provider, not something to push through silently.

Eat smaller and slower. Large meals sit badly when gastric emptying is delayed.

Report symptoms early. Severe or persistent vomiting and diarrhea are the events that turn into dehydration and then into kidney trouble. Providers can adjust the dose or the pace.

Some providers prescribe GLP-1 medications at lower doses than the standard escalation schedule, an approach often called microdosing. That is a prescribing decision made by a licensed provider based on the individual, not a general tolerability strategy, and it is discussed further in our microdosing guide.

Common questions

Do tirzepatide side effects go away?

For most people in the trials, gastrointestinal effects were transient and mild to moderate, occurring mainly during dose escalation [1, 3]. That does not hold for everyone, and some people do not tolerate the medication at any dose.

Are side effects dose-dependent?

Partly. In SURMOUNT-1, nausea and vomiting rates generally rose with dose, though not perfectly: constipation was reported by 16.8% at 5 mg and 11.7% at 15 mg [2]. Kidney injury risk in particular did not appear to be dose-dependent in the published analyses [4]. Individual sensitivity varies.

When should I stop and call a provider?

Severe abdominal pain, persistent vomiting, signs of dehydration such as very dark urine or lightheadedness, symptoms of an allergic reaction, or any sudden severe symptom. Do not wait for a scheduled check-in.

Do compounded formulations have the same side effect profile as the branded products?

This is the wrong question to answer with the trial data above. All the figures in this article come from studies of the FDA-approved products. Compounded formulations are prepared by licensed compounding pharmacies, are not FDA-approved, and have not been evaluated by the FDA for safety, effectiveness, or quality. Their safety profile has not been established through that review process, so the branded trial data should not be read as describing them. A licensed provider is the right person to discuss what is known and unknown about any specific formulation.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review.

Explore Luvo's Weight Loss Program.